APPLIED THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.28 USD | +1.18% |
|
-2.28% | +27.76% |
| Apr. 15 | Applied Therapeutics, Inc. Announces Management Changes | CI |
| Mar. 28 | Applied Therapeutics Shares Slip 13% After FDA Extends Drug Review | DJ |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 505.1 | 495 | 234.6 | 36.52 | 258.7 | 489 | - | - |
| Enterprise Value (EV) 1 | 466.2 | 398.1 | 153.8 | 5.945 | 208.8 | 279.4 | 319 | 355.5 |
| P/E ratio | -7.68 x | -5.14 x | -2.17 x | -0.35 x | -2.36 x | -5.75 x | -13.5 x | 32.6 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | 25.9 x | 63.1 x | 7.18 x | 3.72 x |
| EV / Revenue | - | - | - | - | 20.9 x | 36 x | 4.68 x | 2.7 x |
| EV / EBITDA | -10.2 x | -4.21 x | -1.46 x | -0.07 x | -3.25 x | -3.27 x | -7.94 x | 10.7 x |
| EV / FCF | -12.8 x | -5.09 x | -1.7 x | - | - | -3.43 x | -8.16 x | 4.9 x |
| FCF Yield | -7.79% | -19.6% | -59% | - | - | -29.1% | -12.3% | 20.4% |
| Price to Book | 15.5 x | 6.04 x | 3.75 x | 8.99 x | -16.6 x | 2.7 x | 4.43 x | 4.95 x |
| Nbr of stocks (in thousands) | 18,515 | 22,488 | 26,216 | 48,059 | 77,229 | 114,242 | - | - |
| Reference price 2 | 27.28 | 22.01 | 8.950 | 0.7600 | 3.350 | 4.280 | 4.280 | 4.280 |
| Announcement Date | 3/13/20 | 3/18/21 | 3/10/22 | 3/23/23 | 3/6/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | 9.993 | 7.751 | 68.12 | 131.4 |
| EBITDA 1 | -45.58 | -94.47 | -105.2 | -82.51 | -64.18 | -85.41 | -40.17 | 33.36 |
| EBIT 1 | -45.58 | -94.47 | -105.6 | -82.95 | -64.54 | -88.37 | -47.5 | 17.16 |
| Operating Margin | - | - | - | - | -645.8% | -1,140.03% | -69.73% | 13.06% |
| Earnings before Tax (EBT) 1 | -45.51 | -93.96 | -105.6 | -82.51 | -119.8 | -86.63 | -15.65 | 42.19 |
| Net income 1 | -45.51 | -93.96 | -105.6 | -82.51 | -119.8 | -72.83 | -20.44 | 42.19 |
| Net margin | - | - | - | - | -1,198.47% | -939.52% | -30% | 32.11% |
| EPS 2 | -3.550 | -4.280 | -4.120 | -2.180 | -1.420 | -0.7438 | -0.3170 | 0.1312 |
| Free Cash Flow 1 | -36.31 | -78.21 | -90.73 | - | - | -81.42 | -39.08 | 72.61 |
| FCF margin | - | - | - | - | - | -1,050.38% | -57.37% | 55.25% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | 217.63% |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | 172.08% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 3/13/20 | 3/18/21 | 3/10/22 | 3/23/23 | 3/6/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | 10.66 | - | - | 9.993 | 2.5 | - | 0.7548 | 5.381 | 19.89 |
| EBITDA 1 | - | -27.01 | - | - | - | - | - | - | - | -21 | -20.58 | -21.64 | -22.44 | -20.73 | - |
| EBIT 1 | -28.43 | -27.11 | -23.1 | -21.52 | -19.36 | -18.97 | -10.86 | -17.18 | -15.5 | -21.01 | -21.67 | -23.75 | -25.43 | -24.45 | -14.27 |
| Operating Margin | - | - | - | - | - | - | -101.86% | - | - | -210.23% | -866.94% | - | -3,369.42% | -454.47% | -71.73% |
| Earnings before Tax (EBT) 1 | -28.42 | -27.16 | -23.12 | -25.86 | -19.1 | -14.43 | -10.14 | -29.58 | -42.37 | -37.68 | -21.68 | -22.55 | -22.62 | -19.78 | -13.67 |
| Net income 1 | -28.42 | -27.16 | -23.12 | -25.86 | -19.1 | -14.43 | -10.14 | -29.58 | -42.37 | -37.68 | -15.75 | -19.53 | -19.68 | -17.89 | -10.8 |
| Net margin | - | - | - | - | - | - | -95.09% | - | - | -377.05% | -630.1% | - | -2,607.94% | -332.52% | -54.29% |
| EPS 2 | -1.090 | -1.040 | -0.8800 | -0.9600 | -0.4000 | -0.1600 | -0.1800 | -0.3700 | -0.4700 | -0.3300 | -0.1559 | -0.1831 | -0.1838 | -0.1690 | -0.1000 |
| Dividend per Share 2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/12/21 | 3/10/22 | 5/12/22 | 8/12/22 | 11/9/22 | 3/23/23 | 5/11/23 | 8/10/23 | 11/9/23 | 3/6/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 38.9 | 96.8 | 80.8 | 30.6 | 49.9 | 210 | 170 | 133 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -36.3 | -78.2 | -90.7 | - | - | -81.4 | -39.1 | 72.6 |
| ROE (net income / shareholders' equity) | - | -164% | -146% | -248% | - | - | - | 252% |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share 2 | 1.760 | 3.640 | 2.390 | 0.0800 | -0.2000 | 1.580 | 0.9700 | 0.8600 |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | - | - | - | 64.2 | - | 0.05 | 0.15 | 0.66 |
| Capex / Sales | - | - | - | - | - | 0.71% | 0.23% | 0.51% |
| Announcement Date | 3/13/20 | 3/18/21 | 3/10/22 | 3/23/23 | 3/6/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
4.28
USD
Average target price
11.6
USD
Spread / Average Target
+171.03%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +27.76% | 489M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- APLT Stock
- Financials Applied Therapeutics, Inc.
